Tag Archives: cDNA

Bhagat v. Iancu – Did the Myriad Decision Overrule Funk Bros.?

A September 6th post by Dennis Crouch at PatentlyO (“A Mixture of Known Compounds is Unpatentable without a Transformation“) led me to a closer reading of the cert. petition filed in Bhagat v. Iancu, (Case No. 18-277) an appeal from … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , , | Leave a comment

The Unacknowledged Role of Section 112 in the Myriad Decisions

Guest post from Paul Cole, Lucas & Co., UK; introduction by Warren Woessner. In this interesting note, Paul Cole explores the possible effect on the Fed. Cir. and Supreme Court’s decisions about the patent-eligibility  of “genomic DNA” of the arguable … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Sanofi-Aventis v. Pfizer – Possession and Appreciation Trump Structure

On Tuesday, the Fed. Cir. affirmed a finding by the Board that Pfizer was entitled to an earlier priority date for a claim to  cDNA encoding the IL-13 receptor protein (Sanofi-Aventis v. Pfizer, Inc., App. No. 2012-1345 (Fed. Cir. November … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , | Leave a comment